Illumina Inc is a leading biotechnology company that specializes in the development and manufacturing of advanced genomic sequencing technologies
The company focuses on providing innovative solutions for researchers and healthcare professionals, enabling them to analyze DNA, RNA, and other genomic materials with high accuracy and efficiency. Illumina’s cutting-edge sequencing platforms and reagents support a wide range of applications, including genomics research, clinical diagnostics, and personalized medicine, thereby playing a crucial role in advancing the field of genomics and improving human health.
China banned imports of Illumina's gene sequencers as new U.S. tariffs took effect, cutting its market access while Chinese rivals gain ground in the biotech sector.
What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 10-14, 2025.
Genomics company Pacific Biosciences of California (NASDAQPACB) will be announcing earnings results tomorrow after market hours. Here’s what investors should know.
Shares of genomics company Illumina (NASDAQILMN) fell 7.5% in the morning session after Barclays downgraded the stock to Sell and lowered the price target from $130 to $100. The firm cited several factors for the revision, including "growing uncertainty in China, rising competition from Roche in the clinical market, and weaker-than-expected elasticity in consumables demand."
On Monday, February 10, 2025, the Cathie Wood-led Ark Invest sold nearly $16 million worth of Palantir shares amid a spike in the share price of the company.
Shares of genomics company Illumina (NASDAQILMN) fell 8.6% in the morning session after the company reported fourth-quarter results and provided full-year revenue guidance, which fell below Wall Street's expectations. The guidance did not account for the potential impact of the China Ministry of Commerce's decision to add the company to its 'unreliable entity list.'
Genomics company Illumina (NASDAQILMN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales were flat year on year at $1.1 billion. On the other hand, the company’s full-year revenue guidance of $4.34 billion at the midpoint came in 1.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 6.9% below analysts’ consensus estimates.
It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged up 0.3%, while the Dow Jones slipped 0.1% and small caps held steady.
